New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Piper Jaffray believes Galena's decision to in-license Zuplenz makes sense, as the drug is prescribed by the same the physicians that prescribe its Abstral drug. The firm views the move as in keeping with Galena's strategy to acquire late-stage drugs that add near-term cash flow to cover some of NeuVax's R&D expenses and it keeps its Overweight rating and $6 target on the stock.
News For GALE From The Last 14 Days
Check below for free stories on GALE the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:13 EDTGALEGalena doses first patient in GALE-401 Phase 2 clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use